Cost-Effectiveness Analysis of Daratumumab Monotherapy and Subsequent Therapies in Heavily Treated Relapsed/Refractory Multiple Myeloma: A Feasible Methodology using a Korean Nationwide Population Cohort
This study provides a novel cost-effectiveness framework linking treatment efficacy and real-world costs, supporting predictions of societal costs for future MM therapies.
Authors
- Suein Choi (ORCID: https://orcid.org/0000-0001-5438-7819)
- Seungpil Jung (ORCID: https://orcid.org/0000-0002-8313-8800)
- Seunghoon Han (ORCID: https://orcid.org/0000-0002-9976-5120)
- Soyoung Kim (ORCID: https://orcid.org/0000-0002-8678-5341)
- Jinseon Han
- Kihyun Kım (ORCID: https://orcid.org/0000-0002-5878-8895)
- Sung‐Soo Park (ORCID: https://orcid.org/0000-0002-8826-4136)
- Chang‐Ki Min (ORCID: https://orcid.org/0000-0002-1940-0392)
- C. P. Lee
Institutions
- Samsung Medical Center (KR)
- National Institute for Mathematical Sciences (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Sungkyunkwan University (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-04-15
- DOI
- https://doi.org/10.4143/crt.2025.046
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministry of Food and Drug Safety
- Ministry of Science and ICT, South Korea
- Samsung
- National Institute for Materials Science
- Division of Mathematical Sciences